Stem Cell Therapy finalizes merger with South Korean firm

02/1/2010 | American City Business Journals

Stem Cell Therapy International has completed its merger with South Korean firm Histostem in a deal that will allow it to run Histostem as its wholly owned unit. Stem Cell Therapy, a provider of biological supplies containing new stem cell product lines, plans to operate under the name AmStem.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ